EGFR and head and neck squamous cell carcinoma: Therefore, a vigorous research effort is needed to seek a feasible way to examine EGFR-Arf1 activity in subsets of HNSCC patients in order to better assess or predict the clinical outcomes of HDAC inhibitors.